123767-44-2

Basic information

• Product Name: Benzene, 1-(azidomethyl)-3-methoxy-
• CAS NO: 123767-44-2
• Molecular Formula: C8H9N3O
• Molecular Weight: 163.179
• Mol File: 123767-44-2.mol
• Article Data: 43

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(azidomethyl)-3-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(azidomethyl)-3-methoxy-(123767-44-2)
• EPA Substance Registry System: Benzene, 1-(azidomethyl)-3-methoxy-(123767-44-2)

Safety Data

• Hazardous Substances Data: 123767-44-2(Hazardous Substances Data)

Upstream product

• 591-31-1 3-methoxy-benzaldehyde 
• 78358-11-9 methanesulfonic acid 3-methoxy-benzyl ester 
• 5071-96-5 3-METHOXYBENZYLAMINE 
• 6971-51-3 3-methoxybenzyl alcohol 
• 42051-04-7 3-methoxybenzyl tosylate 
• 824-98-6 m-methoxybenzyl chloride 
• 874-98-6 1-bromomethyl-3-methoxybenzene 

Downstream Products

• 141072-07-3 methyl 1-(3-methoxybenzyl)-1H-1,2,3-triazole-4-carboxylate 
• 141071-94-5 di-tert-butyl 1-(3-methoxybenzyl)-1H-1,2,3-triazole-4,5-dicarboxylate 
• 126800-01-9 1-(3-methoxybenzyl)-4-phenyl-1H-1,2,3-triazole 
• 126800-13-3 1-(3-methoxybenzyl)-5-phenyl-1H-[1,2,3]triazole 
• 126800-25-7 ethyl 1-(3-methoxybenzyl)-1H-1,2,3-triazole-4-carboxylate 
• 14318-66-2 3-methoxy-N-methylaniline 
• 58296-98-3 3-methoxybenzaldehyde N,N-dimethylhydrazone 
• 959922-04-4 N-(3-methoxyphenylmethyl)carbamic acid ethyl ester 
• 1033749-62-0 C₃₁H₂₈N₄O₂ 
• 1033749-60-8 C₂₁H₂₀N₄O₃ 
• 1527-89-5 3-methoxybenzonitrile 
• 1280497-36-0 1-(3-methoxybenzyl)-5-(1-methyl-1H-imidazol-5-yl)-1H-1,2,3-triazole 
• 1345018-94-1 2-[1-(3'-methoxybenzyl)-1,2,3-triazol-4-yl]ethyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
• 1345019-21-7 2-[1-(3'-methoxybenzyl)-1,2,3-triazol-4-yl]ethyl α-D-mannopyranoside 

Relevant articles and documents

Design, Synthesis, and Biological Activity of New Bis-1,2,3-triazole Derivatives Bearing Thiophene-Chalcone Moiety

A series of novel 1,4-substituted bis-aralkyl and aryl 1,2,3-triazoles bearing thiophene chalcones are synthesized via the Claisen condensation of bis propargyl acetophenone intermediate with thiophene-2-carboxaldehyde followed by the Huisgen cycloaddition of the accumulated bis propargyl chalcone intermediate with various aryl and aralkyl azides. Structures of the synthesized compounds are characterized by IR, NMR and mass spectroscopy. The products are tested for antimicrobial and antioxidant activities, and some of those exhibit antibacterial and antifungal activity. The moderate to poor DPPH free radical scavenging activity is determined for some products.

Hit discovery of Mycobacterium tuberculosis inosine 5′-monophosphate dehydrogenase, GuaB2, inhibitors

Tuberculosis remains a global concern. There is an urgent need of newer antitubercular drugs due to the development of resistant forms of Mycobacterium tuberculosis (Mtb). Inosine 5′-monophosphate dehydrogenase (IMPDH), guaB2, of Mtb, required for guanine nucleotide biosynthesis, is an attractive target for drug development. In this study, we screened a focused library of 73 drug-like molecules with desirable calculated/predicted physicochemical properties, for growth inhibitory activity against drug-sensitive MtbH37Rv. The eight hits and mycophenolic acid, a prototype IMPDH inhibitor, were further evaluated for activity on purified Mtb-GuaB2 enzyme, target selectivity using a conditional knockdown mutant of guaB2 in Mtb, followed by cross-resistance to IMPDH inhibitor-resistant SRMV2.6 strain of Mtb, and activity on human IMPDH2 isoform. One of the hits, 13, a 5-amidophthalide derivative, has shown growth inhibitory potential and target specificity against the Mtb-GuaB2 enzyme. The hit, 13, is a promising molecule with potential for further development as an antitubercular agent.

NOVEL DIBENZOOXAPHOSPHININE OXIDE DERIVATIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE DISEASE COMPRISING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel dibenzooxininin oxide derivative compound having various nitrogen-containing substituents introduced at 6-position of a dibenzooxaphosphorin oxide mononuclear, and to the use thereof. The present invention relates to a pharmaceutical composition for preventing or treating degenerative diseases and a health supplement food composition for preventing or treating degenerative diseases, comprising the dibenzooxaphosphorin oxide derivative compound of the present invention.

Synthesis and rational design of new appended 1,2,3-triazole-uracil ensembles as promising anti-tumor agents via in silico vegfr-2 transferase inhibition

Angiogenesis inhibition is a key step towards the designing of new chemotherapeutic agents. In a view to preparing new molecular entities for cancer treatment, eighteen 1,2,3-triazole-uracil ensembles 5a–r were designed and synthesized via the click reaction. The ligands were well characterized using1 H-,13 C-NMR, elemental analysis and ESI-mass spectrometry. The in silico binding propinquities of the ligands were studied sequentially in the active region of VEGFR-2 using the Molegro virtual docker. All the compounds produced remarkable interactions and potentially inhibitory ligands against VEGFR-2 were obtained with high negative binding energies. Drug-likeness was assessed from the ADME properties. Cytotoxicity of the test compounds was measured against HeLa and HUH-7 tumor cells and NIH/3T3 normal cells by MTT assay. Compound 5h showed higher growth inhibition activity than the positive control, 5-fluorouracil (5-FU), against both HeLa and HUH-7 cells with IC50 values of 4.5 and 7.7 μM respectively. Interestingly, the compounds 5a–r did not show any cytotoxicity towards the normal cell lines. The results advance the position of substituted triazoles in the area of drug design with no ambiguity.